Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2021-12-07 Declaration of Voting R…
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (November 30, 2021). This content directly corresponds to regulatory disclosures regarding the total share capital and voting rights, which is a specific type of corporate action/disclosure. While it is a monthly update, it is not a standard financial report (IR, 10-K) or a general regulatory filing (RNS). It is a specific disclosure about capital structure changes/status. Among the provided codes, none perfectly match 'Monthly Share Capital/Voting Rights Disclosure'. However, since it details changes in the capital structure (number of shares), it is most closely related to 'Share Issue/Capital Change' (SHA) or, given its nature as a mandatory regulatory disclosure not fitting other specific financial reports, it could fall under a general regulatory category. Reviewing the definitions, 'SHA' relates to new share issues or splits. This document reports the *current total* resulting from all activities. Given the focus on the total number of shares and voting rights, it is a specific capital structure disclosure. If a more specific code existed, it would be preferred. Since it is a mandatory disclosure about the composition of the capital, and it is not a dividend announcement (DIV) or a transaction in own shares (POS), the closest fit among the options that deal with capital structure is SHA, although it is more of a periodic report on the existing structure. Alternatively, since it is a mandatory regulatory disclosure not covered elsewhere, RNS might be considered. However, because the core content is the share count, SHA is a stronger thematic fit than the general RNS fallback, assuming SHA covers all official reports detailing the capital base. Given the French regulatory context (AMF), these monthly reports are standard. I will classify it as SHA as it directly concerns the capital structure, which is the subject of the report.
2021-12-07 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated November 4, 2021, announcing that the FDA accepted Acticor Biotech's Investigational New Drug (IND) application for glenzocimab for acute ischemic stroke. It details the upcoming Phase 2/3 clinical trial (ACTISAVE), mentions recent IPO activity, and provides updates on other trials (ACTIMIS, GARDEN). This type of announcement, focusing on regulatory milestones (IND acceptance) and clinical trial progression, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a formal announcement of significant operational/regulatory news rather than a full financial report (10-K, IR) or a transcript (CT), the most fitting category is Earnings Release (ER), as these often include key operational highlights following major events like an IPO or regulatory clearance. It is not a proxy statement (DEF 14A), a management discussion (MDA), or a simple dividend notice (DIV). Given the focus on a major regulatory/clinical milestone, ER is the best fit among the provided options, although RNS could also apply if ER was too restrictive. However, ER typically covers key operational news alongside financial context, and this release is clearly highlighting a major operational achievement. FY 2021
2021-11-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Acticor Biotech received clearance from the US FDA to initiate a clinical trial (Phase 2/3 ACTISAVE study) for their drug glenzocimab in acute ischemic stroke patients. It details the study objectives, mentions recent IPO activity, and discusses other ongoing trials (GARDEN for COVID-19). This type of announcement, focusing on clinical development milestones, regulatory interactions (FDA IND acceptance), and general corporate updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about clinical progress rather than a summary of financial results (ER) or a miscellaneous filing (RNS), it most closely aligns with a general corporate announcement. However, given the options, it is a material corporate event announcement. It is not a full Annual Report (10-K), an Audit Report (AR), a Call Transcript (CT), or a specific financial filing. It is a press release detailing significant operational/clinical progress. In many databases, such detailed operational/clinical updates are often categorized under Earnings Release (ER) if they accompany or precede financial reporting, or sometimes as Regulatory Filings (RNS). Since it is a formal announcement of a major operational milestone (FDA IND clearance), and not just a notice to publish a report (RPA), it fits best as an Earnings Release (ER) if we interpret ER broadly as 'periodical results/updates' or RNS as a general regulatory announcement. Given the context of a clinical stage biotech company, FDA clearance is a key performance indicator often highlighted in earnings-related communications. I will classify it as an Earnings Release (ER) as it communicates a major operational achievement that drives future financial outlook, though RNS is a close second.
2021-11-04 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Share Issue/Capital Change Classification · 99% confidence The document announces two related corporate actions: the implementation of a liquidity contract (contrat de liquidité) with Kepler Cheuvreux and the description of a share repurchase program (programme de rachat d'actions). The key terms are 'contrat de liquidité', 'programme de rachat', 'rachat d'actions', and the reference to the Board decision and shareholder authorization (assemblée générale). A share repurchase program, where the company buys back its own shares, directly corresponds to the definition of 'Transaction in Own Shares' (POS). While the liquidity contract is related to market making, the core subject detailed here is the authorization and mechanics of the company acquiring its own stock, which fits POS better than CAP (Capital/Financing Update) or DVA (Voting Results). Since this is a detailed announcement describing the terms and purpose of the buyback program, it is classified as POS.
2021-10-29 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document is a "COMMUNIQUE DE PRESSE PRESS RELEASE" announcing the success of Acticor Biotech's Initial Public Offering (IPO) on Euronext Growth Paris. It details the amount raised (€15.5 M), the offer price (€7.12 per share), the allocation of shares, and the intended use of the funds. This announcement concerns a major financing and capital structure event (the IPO). Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate classification for an IPO announcement detailing the capital raised and structure changes. Although it is a press release, its core subject matter is financing, making CAP more specific than the general 'RPA' or 'RNS'. The document length is substantial (over 26k characters), indicating it is the primary announcement, not just a notification of a report.
2021-10-27 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.